Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie

Gynecologic Oncology

Volumn 129, Issue 3, 2013, Pages 495-499

  Emons, Günter ^a   Günthert, Andreas ^a,j   Thiel, Falk C ^b   Camara, Oumar ^c,k   Strauss, Hans Georg ^d   Breitbach, Georg Peter ^e,l   Kölbl, Heinz ^f,m   Reimer, Toralf ^g   Finas, Dominique ^h,n   Rensing, Klaus ^i,o  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e City Hospital   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j UNIVERSITY OF BERN   (Switzerland)

^k Hufeland Klinikum GmbH Bad Langensalza   (Germany)

^l Marienhausklinik St Josef Kohlhof   (Germany)

^m UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

ⁿ EVANGELISCHES KRANKENHAUS   (Germany)

^o Asklepios Unternehmenszentrale   (Germany)

more..

Author keywords

Endometrial cancer; Fulvestrant; Phase II study

Indexed keywords

FULVESTRANT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHMA; BONE PAIN; CANCER MORTALITY; CANCER RECURRENCE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; ENDOMETRIUM CANCER; FATIGUE; FEMALE; GERMANY; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; METASTASIS; NAUSEA; NIGHT SWEAT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84877582557     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.02.039     Document Type: Article

References (21)

1. C.E. Humber, J.F. Tierney, R.P. Symonds, M. Collingwood, J. Kirwan, and C. Williams Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration Ann Oncol 18 2007 409 420
2. S.M. Temkin, and G. Fleming Current treatment of metastatic endometrial cancer Cancer Control 16 2009 38 45
3. M.S. Carey, C. Gawlik, M. Fung-Kee-Fung, A. Chambers, T. Oliver on behalf of the Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group Systematic review of systemic therapy for advanced or recurrent endometrial cancer Gynecol Oncol 101 2006 158 167
4. F. Kokka, E. Brockbank, D. Oram, C. Gallagher, and A. Bryant Hormonal therapy in advanced or recurrent endometrial cancer Art. No.: CD007926 Cochrane Database Syst Rev 12 2010 10.1002/14651858. DC007926.pub2
5. T. Thigpen, M.F. Brady, H.D. Homesley, J.T. Sager, and J. Bell Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 19 2001 364 367
6. L.E. Rutquist Stockholm Breast Cancer Study Group Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer Acta Oncol 46 2007 133 145
7. A. Di Leo, G. Jerusalem, L. Petruzelka, R. Torres, I.N. Bondarenko, and R. Khasanov Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 2010 4594 4600
8. R.M. O'Regan, A. Cisneros, G.M. England, J.L. Mac Gregor, H.P. Muenzner, and V.J. Assikis Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrioid cancer growth J Natl Cancer Inst 90 1998 1552 1558
9. National Cancer Institute Common toxicity criteria, toxical scale, version 2.0 http://www.cancer.gov 1999
10. WHO WHO handbook for reporting results of cancer treatment Offset Publication 48 1979 World Health Organisation Geneva (Switzerland)
11. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10
12. J.T. Thigpen, M.F. Brady, R.D. Alvarez, M.D. Adelson, H.D. Homesley, and M. Manetta Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group J Clin Oncol 17 1999 1736 1744
13. S.S. Lentz, M.F. Brady, F.J. Major, G.C. Reid, and J.T. Soper High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 14 1996 357 361
14. P.G. Rose, V.L. Brunetto, L. VanLe, J. Bell, J.L. Walker, and R.B. Lee A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 78 2000 212 216
15. B.B.Y. Ma, A. Oza, E. Eisenhauer, G. Stanimir, M. Carey, and W. Chapman The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group Int J Gynecol Cancer 14 2004 650 658
16. A.L. Covens, V. Filiaci, P. Gersell, C.V. Lutman, A. Bonebrake, and Y.C. Lee Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 120 2011 185 188
17. A. Howell, and J. Bergh Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer J Clin Oncol 28 2010 4548 4550
18. G.F. Fleming, V.L. Brunetta, and D. Cella Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastin in advanced endometrial carcinoma: a Gynecologic Oncology Group study J. Clin Oncol 2004 2153 2166
19. A. Delmonte, and C. Sessa Molecule-targeted agents in endometrial cancer Curr Opin Oncol 20 2008 554 559
20. M.A. Hoffmann, and A. Khan Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (faslodex) after prior progestin and anastrozole therapy Gynecol Oncol 100 2006 439 441
21. M.P. Lux, E.M. Wenkel, K. Beckmann, M.W. Beckmann, and F. Thiel Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie 29 2006 577 588